Arterial hypertension and anticancer drug therapy: pathophysiological relationships and clinical significance
https://doi.org/10.34215/1609-1175-2022-4-5-10
Abstract
Arterial hypertension (AH) is one of the most common cardiovascular complications of anticancer drug therapy. In this review article, we consider the main groups of anticancer drugs that may cause the development of iatrogenic AH, the pathophysiological mechanisms of increased blood pressure, as well as the clinical significance of AH developed during treatment with cytostatics and targeted drugs in the practice of an oncologist and a cardiologist. It was found that AH is frequently associated with the use of angiogenesis inhibitors, as well as alkylating cytostatics, antimetabolites, taxanes, and proteasome inhibitors. In addition, erythropoietins, glucocorticosteroids, and non-steroidal anti-inflammatory drugs used as part of supportive therapy may contribute to an increase in blood pressure. Management of hypertension in cancer patients is an important part of antitumor treatment therapy whose implementation contributes to improving their quality of life. Research into various clinical and pathophysiological aspects of cardiovascular disorders in cancer patients is becoming increasingly relevant, which is indicated by the rapid development of cardio-oncology, a new interdisciplinary field of knowledge aimed at developing practical recommendations for the prevention, diagnosis, and treatment of cardiovascular toxicity caused by anticancer therapy.
About the Authors
T. S. Satalkina
Far Eastern Federal University
Russian Federation
Russian Federation
Tatyana S. Satalkina, postgraduate at the Department of Clinical Medicine
690922, Vladivostok, Russian Island, 10 Ajax Bay, FEFU Campus, building М (25)
T. A. Brodskaya
Far Eastern Federal University; Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
B. I. Geltser
Far Eastern Federal University
Russian Federation
Russian Federation
Vladivostok
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209–49. doi: 10.3322/caac.21660
2. Hilgendorf I, Bergelt C, Bokemeyer C, Kaatsch P, Seifart U, Stein A, Langer T. Long-Term Follow-Up of Children, Adolescents, and Young Adult Cancer Survivors. Oncology research and treatment. 2021;44(4):184–89. doi: 10.1159/000514381
3. Chazova IE, Oshchepkova EV, Kirillova MYu, Stenina MB. Risk of hypertension development in patients with oncological diseases under anticancer treatment. Consilium Medicum. 2016;18(1):16–20 (In Russ.)
4. Cohen JB, Geara AS, Hogan JJ, Townsend RR. Hypertension in Cancer Patients and Survivors:Epidemiology, Diagnosis, and Management. JACC. Cardio Oncology. 2019;1(2):238–51. doi: 10.1016/j.jaccao.2019.11.009
5. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Texas Heart Institute journal. 2011;38(3):263–5.
6. Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors:understanding and managing a new syndrome. The Canadian journal of cardiology. 2014;30(5):534–43. doi: 10.1016/j.cjca.2014.02.011
7. Abi Aad S, Pierce M, Barmaimon G, Farhat FS, Benjo A, Mouhayar E. Hypertension induced by chemotherapeutic and immunosuppresive agents:a new challenge. Critical reviews in oncology/hematology. 2015;93(1):28–35. doi: 10.1016/j.critrevonc.2014.08.004
8. Geltser ВI, Kotelnikov VN, Vetrova ОО, Karpov RS. Masked arterial hypertension: prevalence, pathophysiological determinants and clinical significance. Russian Journal of Cardiology. 2019;(9):92–8 (In Russ.) doi: 10.15829/1560-4071-2019-9-92-98
9. Tini G, Sarocchi M, Tocci G, Arboscello E, Ghigliotti G, Novo G, Brunelli C, Lenihan D, Volpe M, Spallarossa P. Arterial hypertension in cancer: The elephant in the room. International journal of cardiology. 2019;281:133–9. doi: 10.1016/j.ijcard.2019.01.082
10. Małyszko J, Małyszko M, Kozlowski L, Kozlowska K, Małyszko J. Hypertension in malignancy-an underappreciated problem. Oncotarget. 2018;9(29):20855–71. doi: 10.18632/oncotarget.25024
11. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed March 27, 2018).
12. Sharafeev AZ, Zhavoronkov VV, Zinchenko SV, Khalirakhmanov A.F. Cardiooncology – a new direction in cardiology. Practical medicine. 2020;18(1):38–42 (In Russ.) doi: 10.32000/2072-1757-2020-1-38-42
13. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip G, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European heart journal. 2017;19(1):9–42. doi: 10.1002/ejhf.654
14. Vasyuk YuA, Gendlin GE, Emelina EI, Shupenina EYu, Ballyuzek MF, Barinova IV, Vitsenya MV, Davydkin IL, Dundua D.P, Duplyakov DV, Zateishchikov DA, Zolotovskaya IA, Konradi AO, Lopatin YuM, Moiseeva OM, Nedogoda SV, Nedoshivin AO, Nikitin IG, Poltavskaya MG, Potievskaya VI, Repin AN, Sumin АN, Zotova LA, Tumyan GS, Shlyakhto EV, Khatkov IE, Yakushin SS, Belenkov YuN. Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity in anticancer therapy. Russian Journal of Cardiology. 2021;26(9):4703 (In Russ.) doi: 10.15829/1560-4071-2021-4703
15. Дворецкий Л.И. Ятрогения в практике интерниста. Терапевтический архив. 2019;91 (1):16–128. doi: 10.26442/00403660.2019.01.000041. [Dvoretsky LI. Iatrogenia in internist practice. Therapeutic Archive. 2019;91(1):16–128 (In Russ.)]. doi: 10.26 442/00403660.2019.01.000041
16. Versmissen J, Mirabito Colafella KM, Koolen S, Danser A. Vascular Cardio-Oncology:Vascular Endothelial Growth Factor inhibitors and hypertension. Cardiovasc Res. 2019;115(5):904–914. doi: 10.1093/cvr/cvz022
17. Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients:A systematic review and comprehensive metaanalysis. Oncotarget. 2017;8(31):51492–506. doi: 10.18632/oncotarget.18190
18. Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncology letters. 2021;21(4):315. doi: 10.3892/ol.2021.12576
19. Corr BR, Breed C, Sheeder J, Weisdack S, Behbakht K. Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy? Gynecologic oncology reports. 2016;17:65–8. doi: 10.1016/j.gore.2016.06.002
20. Pandey AK, Singhi EK, Arroyo JP, Ikizler TA, Gould ER, Brown J, Beckman JA, Harrison DG, Moslehi J. Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease. Hypertension. 2018;71(2):e1– e8. doi: 10.1161/HYPERTENSIONAHA.117.10271
21. Di Lisi D, Madonna R, Zito C, Bronte E, Badalamenti G, Parrella P, Monte I, Tocchetti CG, Russo A, Novo G. Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. International journal of cardiology. 2017;227:11–7. doi: 10.1016/j.ijcard.2016.11.174
22. Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 2010;56(4):675–81. doi: 10.1161/HYPERTENSIONAHA.109.149690
23. Boursiquot BC, Zabor EC, Glezerman IG, Jaimes EA. Hypertension and VEGF (Vascular Endothelial Growth Factor) Receptor Tyrosine Kinase Inhibition: Effects on Renal Function. Hypertension. 2017;HYPERTENSIONAHA.117.09275. doi: 10.1161/HYPERTENSIONAHA.117.09275
24. Touyz RM, Herrmann S, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. J Am Soc Hypertension. 2018;12(6):409–25. doi: 10.1016/j.jash.2018.03.008
25. Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardiooncology. 2021;7(1):14. doi: 10.1186/s40959-021-00101-2
26. Ancker OV, Wehland M, Bauer J, Infanger M, Grimm D. The Adverse Effect of Hypertension in the Treatment of Thyroid Cancer with Multi-Kinase Inhibitors. International Journal of Molecular Sciences. 2017;18(3):625. https://doi.org/10.3390/ijms18030625
27. Li M, Kroetz DL. Bevacizumab-induced hypertension: Clinical presentation and molecular understanding. Pharmaco logy & therapeutics. 2018;182:152–60. doi: 10.1016/j.pharmthera.2017.08.012
28. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, Kaymakcalan MD, Williams JS. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311–9. doi: 10.1002/cncr.28972
29. Donskov F, Michaelson MD, Puzanov I, Davis MP, Bjarnason GA, Motzer RJ, Goldstein D, Lin X, Cohen DP, Wiltshire R, Rini BI. Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients. British journal of cancer. 2015;113(11):1571–80. doi: 10.1038/bjc.2015.368
30. Miyake M, Kuwada M, Hori S, Morizawa Y, Tatsumi Y, Anai S, Hosokawa Y, Hayashi Y, Tomioka A, Otani T, Otsuka K, Nakagawa Y, Nakai Y, Samma S, Tanaka N, Fujimoto K. The best objective response of target lesions and the incidence of treatmentrelated hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective study. BMC research notes. 2016;9:79. doi: 10.1186/s13104-016-1895-8
31. Dionísio de Sousa IJ, Ferreira J, Rodrigues J, Bonito N, Jacinto P, Marques M, Ribeiro J, Pais A, Gervásio H. Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. ESMO Open. 2016;1(3):e000045. doi: 10.1136/esmoopen-2016-000045
32. Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos M.A, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer treatment reviews. 2012;38(5):473–83. doi: 10.1016/j.ctrv.2011.09.002
33. Cameron AC, Touyz RM, Lang NN. Vascular Complications of Cancer Chemotherapy. The Canadian journal of cardiology. 2016;32(7):852–62. doi: 10.1016/j.cjca.2015.12.023
34. Al-Hashmi S, Boels PJ, Zadjali F, Sadeghi B, Sällström J, Hultenby K, Hassan Z, Arner A, Hassan M. Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase. PLoS One. 2012;7(1):e30897. doi: 10.1371/journal.pone.0030897
35. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, Orlowski RZ, Ludwig H, Facon T, Hajek R, Weisel K, Hungria V, Minuk L, Feng S, Zahlten-Kumeli A, Kimball AS, Moreau P. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(10):1327–37. doi: 10.1016/S14702045(17)30578-8
36. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. Integrated safety profile of single-agent carfilzomib:experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–61. doi: 10.3324/haematol.2013.089334
37. Hasinoff BB, Patel D, Wu X. Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib. Cardiovascular toxicology. 2017;17(3):237–50. doi: 10.1007/s12012-016-9378-7
38. Morales JM. Influence of the new immunosuppressive combinations on arterial hypertension after renal transplantation. Kidney international. Supplement. 2002;82:S81–7. doi: 10.1046/j.15231755.62.s82.16.x
39. Haddad EM, McAlister VC, Renouf E, Malthaner R, Kjaer MS, Gluud LL. Cyclosporin versus tacrolimus for liver transplanted patients. The Cochrane database of systematic reviews. 2006;4:CD005161. doi: 10.1002/14651858CD005161.pub2
40. van Hell AJ, Haimovitz-Friedman A, Fuks Z, Tap WD, Kolesnick R. Gemcitabine kills proliferating endothelial cells exclusively via acid sphingomyelinase activation. Cell Signal. 2017;34:86–91. doi: 10.1016/j.cellsig.2017.02.021
41. Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, Valeria Bianchi G, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Ji Y, Wang C, Deore U, Chakravartty A, Zarate JP, Taran T, Fasching PA. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial:updated overall survival. Annals of oncology. 2021;32(8):1015–24. doi: 10.1016/j.annonc.2021.05.353
42. Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, Shparyk YV, Thummala A, Voitko N, Bananis E, McRoy L, Wilner K, Huang X, Kim S, Slamon DJ, Ettl J. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2advanced breast cancer (PALOMA-1, TRIO-18). Breast cancer research and treatment. 2020;183(2):419–28. doi: 10.1007/s10549-020-05755-7
43. Sledge G.W, Jr Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, LlombartCussac A. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/ HER2Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of clinical oncology. 2017;35(25):2875–84. doi: 10.1200/JCO.2017.73.7585
44. Papageorgiou C, Zagouri F, Tampakis K, Georgakopoulou R, Manios E, Kafouris P, Benetos G, Koutagiar I, Anagnostopoulos C, Dimopoulos M.A, Toutouzas K. Vascular Inflammation and Cardiovascular Burden in Metastatic Breast Cancer Female Patients Receiving Hormonal Treatment and CDK 4/6 Inhibitors or Everolimus. Frontiers in cardiovascular medicine. 2021;8:638895. doi: 10.3389/fcvm.2021.638895
45. Schmitz ML, Kracht M. Cyclin-dependent kinases as coregulators of inflammatory gene expression. Trends in pharmacological sciences. 2016;37:101–13. doi: 10.1016/j.tips.2015.10.004
46. Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune system in hypertension. Physiological reviews. 2017;97:1127–64. doi: 10.1152/physrev.00031.2016
47. Schoen MW, Hoque S, Witherspoon BJ, Schooley B, Sartor O, Yang YT, Yarnold PR, Knopf KB, Hrushesky W, Dickson M, Chen BJ, Nabhan C, Bennett CL. End of an era for erythropoiesis-stimulating agents in oncology. International journal of cancer. 2020;146(10):2829–35. doi: 10.1002/ijc.32917
48. Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S. Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy induced anemia: a systematic review. Clinical therapeutics. 2014;36(4):594–610. doi: 10.1016/j.clinthera.2014.02.007
49. Souza VB, Silva EN, Ribeiro ML, Martins WA. Hypertension in patients with cancer. Arquivos brasileiros de cardiologia. 2015;104(3):246–52. doi: 10.5935/abc.20150011
Review
For citations:
Satalkina T.S., Brodskaya T.A., Geltser B.I. Arterial hypertension and anticancer drug therapy: pathophysiological relationships and clinical significance. Pacific Medical Journal. 2022;(4):5-10. (In Russ.) https://doi.org/10.34215/1609-1175-2022-4-5-10
Views:
1877
Email this article 